| Cancer type | Cell line | Effects | Reference |
| Adenoid cystic | ACC | Inhibition of MMP-9, antimetastatic | [89] | Bladder | RT4, J82, 5637, T24 | Downregulation of VEGF, upregulation PAL-1, endostatin, angiostatin, and THBS-1 | [90] | Breast | MDA-MB-231 | Activation of ERK1/2 pathway, induction of cell cycle arrest at the G2/M phase, downregulation of Cdk1, cyclin B1, and Cdc25 C | [91] | Cervical | HeLa | Activation of caspase-9 and -3 | [92] | Colon | HT-29 | Inhibition of NF-ĸB | [93] | | Activation of caspase-3 and p38/MAPK | [94] | HCT-116 | Anti-roliferation, cell cycle arrest at the G2/M phase | (Mizushina et al., 2013) | | Inhibition of MMP-9, COX-2, Ang-1, VASP, VEGF, anti-etastatic | [95] | SW-480 | Cell cycle arrest at the G2/M phase, apoptosis via ATM/p53 pathway | [53] |
| Gastric | HGC-27 | Induction of cell cycle arrest at the G2/M phase | [96] | Lung | A549 | Reduction of ERK1/2, PI3K/Akt and MMP-2 | [97] | Melanoma | B16F10 | Downregulation of Snail | [98] | Oral squamous | HSC-3 | Downregulation of VEGF, anti-invasion | [99] | Thyroid | CAL-62, ACC 448, CGTH-W1, ACC 360 | Cytotoxicity, downregulation of VEGF, hTERT, NF-ĸB genes, upregulation of PTEN and p21 mRNA | [100] |
|
|